Intranasal Oxytocin in Hypothalamic Obesity

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

April 30, 2021

Study Completion Date

May 31, 2022

Conditions
CraniopharyngiomaHypothalamic Obesity
Interventions
DRUG

Syntocinon

The active substance of Syntocinon is a synthetic nonapeptide identical to the posterior pituitary hormone oxytocin.

DRUG

Placebo (for Syntocinon)

The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.

Trial Locations (1)

19104

Children's Hospital of Philadelphia, Philadelphia

All Listed Sponsors
lead

Shana McCormack, MD

OTHER

NCT02849743 - Intranasal Oxytocin in Hypothalamic Obesity | Biotech Hunter | Biotech Hunter